Found: 48
Select item for more details and to access through your institution.
Monocyte-to-platelets ratio (MPR) at diagnosis is associated with inferior progression-free survival in patients with mantle cell lymphoma: a multi-center real-life survey.
- Published in:
- Annals of Hematology, 2024, v. 103, n. 8, p. 3043, doi. 10.1007/s00277-024-05752-6
- By:
- Publication type:
- Article
Innovative Combinations, Cellular Therapies and Bispecific Antibodies for Chronic Lymphocytic Leukemia: A Narrative Review.
- Published in:
- Cancers, 2024, v. 16, n. 7, p. 1290, doi. 10.3390/cancers16071290
- By:
- Publication type:
- Article
Real-World Outcome of Treatment with Single-Agent Ibrutinib in Italian Patients with Chronic Lymphocytic Leukemia: Final Results of the EVIdeNCE Study.
- Published in:
- Cancers, 2024, v. 16, n. 6, p. 1228, doi. 10.3390/cancers16061228
- By:
- Publication type:
- Article
Baseline IgM Amounts Can Identify Patients with Poor Outcomes: Results from a Real-Life Single-Center Study on Classical Hodgkin Lymphoma.
- Published in:
- Cancers, 2024, v. 16, n. 4, p. 826, doi. 10.3390/cancers16040826
- By:
- Publication type:
- Article
Efficacy and safety of tixagevimab‐cilgavimab versus SARS‐CoV‐2 breakthrough infection in the hematological conditions.
- Published in:
- Cancer (0008543X), 2024, v. 130, n. 1, p. 41, doi. 10.1002/cncr.35005
- By:
- Publication type:
- Article
Ibrutinib as first line therapy in chronic lymphocytic leukemia patients over 80 years old: A retrospective real‐life multicenter Italian cohort.
- Published in:
- Hematological Oncology, 2024, v. 42, n. 1, p. 1, doi. 10.1002/hon.3249
- By:
- Publication type:
- Article
Patients' preferences for chronic lymphocytic leukemia treatment: The CHOICE study.
- Published in:
- Hematological Oncology, 2024, v. 42, n. 1, p. 1, doi. 10.1002/hon.3216
- By:
- Publication type:
- Article
XPO1 mutations identify early‐stage CLL characterized by shorter time to first treatment and enhanced BCR signalling.
- Published in:
- British Journal of Haematology, 2023, v. 203, n. 3, p. 416, doi. 10.1111/bjh.19052
- By:
- Publication type:
- Article
The time to first treatment is an independent predictor of overall survival in chronic lymphocytic leukemia.
- Published in:
- American Journal of Hematology, 2023, v. 98, n. 7, p. E157, doi. 10.1002/ajh.26927
- By:
- Publication type:
- Article
Prediction of outcomes in chronic lymphocytic leukemia patients treated with ibrutinib: Validation of current prognostic models and development of a simplified three‐factor model.
- Published in:
- American Journal of Hematology, 2022, v. 97, n. 5, p. E176, doi. 10.1002/ajh.26502
- By:
- Publication type:
- Article
Reduced Absolute Count of Monocytes in Patients Carrying Hematological Neoplasms and SARS-CoV2 Infection.
- Published in:
- Cancers, 2022, v. 14, n. 5, p. 1173, doi. 10.3390/cancers14051173
- By:
- Publication type:
- Article
Coexisting conditions and concomitant medications do not affect venetoclax management and survival in chronic lymphocytic leukemia.
- Published in:
- Therapeutic Advances in Hematology, 2022, v. 13, p. 1, doi. 10.1177/20406207221127550
- By:
- Publication type:
- Article
Effectiveness of ibrutinib as first‐line therapy for chronic lymphocytic leukemia patients and indirect comparison with rituximab‐bendamustine: Results of study on 486 cases outside clinical trials.
- Published in:
- American Journal of Hematology, 2021, v. 96, n. 8, p. E269, doi. 10.1002/ajh.26201
- By:
- Publication type:
- Article
TP53 disruption as a risk factor in the era of targeted therapies: A multicenter retrospective study of 525 chronic lymphocytic leukemia cases.
- Published in:
- American Journal of Hematology, 2021, v. 96, n. 8, p. E306, doi. 10.1002/ajh.26235
- By:
- Publication type:
- Article
Prognostic Impact and Risk Factors of Infections in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib.
- Published in:
- Cancers, 2021, v. 13, n. 13, p. 3240, doi. 10.3390/cancers13133240
- By:
- Publication type:
- Article
Assessment of the 4‐factor score: Retrospective analysis of 586 CLL patients receiving ibrutinib. A campus CLL study.
- Published in:
- American Journal of Hematology, 2021, v. 96, n. 5, p. E168, doi. 10.1002/ajh.26127
- By:
- Publication type:
- Article
A brief rituximab, bendamustine, mitoxantrone (R‐BM) induction followed by rituximab consolidation in elderly patients with advanced follicular lymphoma: a phase II study by the Fondazione Italiana Linfomi (FIL).
- Published in:
- British Journal of Haematology, 2021, v. 193, n. 2, p. 280, doi. 10.1111/bjh.17283
- By:
- Publication type:
- Article
Comparison of ibrutinib and idelalisib plus rituximab in real‐life relapsed/resistant chronic lymphocytic leukemia cases.
- Published in:
- European Journal of Haematology, 2021, v. 106, n. 4, p. 493, doi. 10.1111/ejh.13573
- By:
- Publication type:
- Article
Validation of a survival-risk score (SRS) in relapsed/refractory CLL patients treated with idelalisib–rituximab.
- Published in:
- 2020
- By:
- Publication type:
- Letter
Brentuximab vedotin in association with bendamustine in refractory or multiple relapsed Hodgkin lymphoma. A retrospective real‐world study.
- Published in:
- European Journal of Haematology, 2020, v. 104, n. 6, p. 581, doi. 10.1111/ejh.13400
- By:
- Publication type:
- Article
Monocytic Myeloid Derived Suppressor Cells in Hematological Malignancies.
- Published in:
- International Journal of Molecular Sciences, 2019, v. 20, n. 21, p. 5459, doi. 10.3390/ijms20215459
- By:
- Publication type:
- Article
Outcome of transformed follicular lymphoma worsens according to the timing of transformation and to the number of previous therapies. A retrospective multicenter study on behalf of Fondazione Italiana Linfomi (FIL).
- Published in:
- British Journal of Haematology, 2019, v. 185, n. 4, p. 713, doi. 10.1111/bjh.15816
- By:
- Publication type:
- Article
Immune off‐target effects of Brentuximab Vedotin in relapsed/refractory Hodgkin Lymphoma.
- Published in:
- British Journal of Haematology, 2019, v. 185, n. 3, p. 468, doi. 10.1111/bjh.15801
- By:
- Publication type:
- Article
Predictive value of the CLL‐IPI in CLL patients receiving chemo‐immunotherapy as first‐line treatment.
- Published in:
- European Journal of Haematology, 2018, v. 101, n. 5, p. 703, doi. 10.1111/ejh.13149
- By:
- Publication type:
- Article
Immunoglobulin heavy chain variable region gene and prediction of time to first treatment in patients with chronic lymphocytic leukemia: Mutational load or mutational status? Analysis of 1003 cases.
- Published in:
- American Journal of Hematology, 2018, v. 93, n. 9, p. E216, doi. 10.1002/ajh.25206
- By:
- Publication type:
- Article
NOTCH1 mutational status in chronic lymphocytic leukaemia: clinical relevance of subclonal mutations and mutation types.
- Published in:
- British Journal of Haematology, 2018, v. 182, n. 4, p. 597, doi. 10.1111/bjh.14843
- By:
- Publication type:
- Article
Prognostic meaning of neutrophil to lymphocyte ratio (NLR) and lymphocyte to monocyte ration (LMR) in newly diagnosed Hodgkin lymphoma patients treated upfront with a PET-2 based strategy.
- Published in:
- Annals of Hematology, 2018, v. 97, n. 6, p. 1009, doi. 10.1007/s00277-018-3276-y
- By:
- Publication type:
- Article
Mutations of BRAF and BIRC3 Identify a Subgroup of Chronic Lymphocytic Leukemia with Very Poor Prognosis upon FCR Treatment.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2017, v. 17, p. S11, doi. 10.1016/j.clml.2017.09.039
- By:
- Publication type:
- Article
The Prognostic Value of the Myeloid-Mediated Immunosuppression Marker Arginase-1 in Classic Hodgkin Lymphoma.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2016, v. 16, p. S66, doi. 10.1016/j.clml.2016.07.096
- By:
- Publication type:
- Article
Mesenchymal Stem Cells (MSC) Regulate Activation of Granulocyte-Like Myeloid Derived Suppressor Cells (G-MDSC) in Chronic Myeloid Leukemia Patients.
- Published in:
- PLoS ONE, 2016, v. 11, n. 7, p. 1, doi. 10.1371/journal.pone.0158392
- By:
- Publication type:
- Article
Prognostic roles of absolute monocyte and absolute lymphocyte counts in patients with advanced-stage follicular lymphoma in the rituximab era: an analysis from the FOLL05 trial of the Fondazione Italiana Linfomi.
- Published in:
- British Journal of Haematology, 2015, v. 169, n. 4, p. 544, doi. 10.1111/bjh.13332
- By:
- Publication type:
- Article
Circulating myeloid-derived suppressor cells correlate with clinical outcome in Hodgkin Lymphoma patients treated up-front with a risk-adapted strategy.
- Published in:
- British Journal of Haematology, 2015, v. 168, n. 5, p. 689, doi. 10.1111/bjh.13198
- By:
- Publication type:
- Article
Salvage therapy with pegylated liposomal doxorubicin, bortezomib, cyclophosphamide, and dexamethasone in relapsed/refractory myeloma patients.
- Published in:
- European Journal of Haematology, 2014, v. 93, n. 3, p. 207, doi. 10.1111/ejh.12325
- By:
- Publication type:
- Article
Myeloid Derived Suppressor Cells (MDSCs) Are Increased and Exert Immunosuppressive Activity Together with Polymorphonuclear Leukocytes (PMNs) in Chronic Myeloid Leukemia Patients.
- Published in:
- PLoS ONE, 2014, v. 9, n. 7, p. 1, doi. 10.1371/journal.pone.0101848
- By:
- Publication type:
- Article
Prognostic assessment and treatment of primary gastric lymphomas: how endoscopic ultrasonography can help in tailoring patient management.
- Published in:
- 2014
- By:
- Publication type:
- Journal Article
Salvage Therapy of Multiple Myeloma: The New Generation Drugs.
- Published in:
- BioMed Research International, 2014, v. 2014, p. 1, doi. 10.1155/2014/456037
- By:
- Publication type:
- Article
Salvage therapy of multiple myeloma: the new generation drugs.
- Published in:
- 2014
- By:
- Publication type:
- Journal Article
Detection of TP53 dysfunction in chronic lymphocytic leukemia by an in vitro functional assay based on TP53 activation by the non-genotoxic drug Nutlin-3: a proposal for clinical application.
- Published in:
- Journal of Hematology & Oncology, 2013, v. 6, n. 1, p. 3, doi. 10.1186/1756-8722-6-83
- By:
- Publication type:
- Article
SPARC expression in CML is associated to imatinib treatment and to inhibition of leukemia cell proliferation.
- Published in:
- BMC Cancer, 2013, v. 13, n. 1, p. 1, doi. 10.1186/1471-2407-13-60
- By:
- Publication type:
- Article
SPARC expression in CML is associated to imatinib treatment and to inhibition of leukemia cell proliferation.
- Published in:
- 2013
- By:
- Publication type:
- journal article
Endoscopic ultrasonography in gastric lymphomas: appraisal on reliability in long-term follow-up.
- Published in:
- 2012
- By:
- Publication type:
- journal article
Endoscopic ultrasonography in gastric lymphomas: appraisal on reliability in long-term follow-up Endoscopic ultrasonography in gastric lymphomas: appraisal on reliability in long-term follow-up.
- Published in:
- Hematological Oncology, 2012, v. 30, n. 4, p. 180, doi. 10.1002/hon.1022
- By:
- Publication type:
- Article
Disulfiram, an old drug with new potential therapeutic uses for human hematological malignancies.
- Published in:
- International Journal of Cancer, 2012, v. 131, n. 9, p. 2197, doi. 10.1002/ijc.27482
- By:
- Publication type:
- Article
Effects of second-generation tyrosine kinase inhibitors towards osteogenic differentiation of human mesenchymal cells of healthy donors.
- Published in:
- Hematological Oncology, 2012, v. 30, n. 1, p. 27, doi. 10.1002/hon.988
- By:
- Publication type:
- Article
Analysis of the coding genome of diffuse large B-cell lymphoma.
- Published in:
- Nature Genetics, 2011, v. 43, n. 9, p. 830, doi. 10.1038/ng.892
- By:
- Publication type:
- Article
Inactivating mutations of acetyltransferase genes in B-cell lymphoma.
- Published in:
- Nature, 2011, v. 471, n. 7337, p. 189, doi. 10.1038/nature09730
- By:
- Publication type:
- Article
Imatinib increases cytotoxicity of melphalan and their combination allows an efficient killing of chronic myeloid leukemia cells.
- Published in:
- European Journal of Haematology, 2011, v. 86, n. 3, p. 216, doi. 10.1111/j.1600-0609.2010.01570.x
- By:
- Publication type:
- Article
Valproate enhances imatinib-induced growth arrest and apoptosis in chronic myeloid leukemia cells.
- Published in:
- Cancer (0008543X), 2006, v. 106, n. 5, p. 1188, doi. 10.1002/cncr.21725
- By:
- Publication type:
- Article